Literature DB >> 24171373

Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008-2012).

Kathryn M Pratschke1, Matt J Atherton, Jack A Sillito, Catherine G Lamm.   

Abstract

OBJECTIVE: To evaluate a modified proportional margins approach to resection of mast cell tumors (MCTs) in dogs.
DESIGN: Retrospective case series. ANIMALS: 40 dogs with subcutaneous and cutaneous MCTs undergoing curative intent surgery. PROCEDURES: Medical records were searched to identify dogs with a cytologically or histologically confirmed diagnosis of MCT that had not previously been treated surgically and that had undergone full oncological staging. In those dogs, tumors were resected with lateral margins equivalent to the widest measured diameter of the tumor and a minimum depth of 1 well-defined fascial plane deep to the tumor. Surgical margins were evaluated histologically. Cutaneous tumors were graded by use of the Patnaik system and the 2-tier system described by Kiupel et al. The prognosis for subcutaneous tumors was assessed in accordance with published recommendations. Follow-up information on dog health status was obtained through clinical examination, the dog owners, and the referring veterinarians.
RESULTS: The 40 dogs had 47 tumors. Forty-one (87%) tumors were cutaneous, and 6 (13%) were subcutaneous. On the basis of the Patnaik system, 21 (51%) cutaneous tumors were considered grade I, 18 (44%) were considered grade II, and 2 (5%) were considered grade III. On the basis of the Kiupel system, 37 (90%) cutaneous tumors were considered low grade, and 4 (10%) were considered high grade. The prognosis for the 6 subcutaneous tumors was classified as likely resulting in a shorter (2) or longer (4) survival time. Forty tumors were deemed to have been excised with clear margins and 7 with incomplete margins. Local recurrence was not recorded for any dog but was suspected for 1 (2%) tumor, although not confirmed. Interval from tumor excision to follow-up ranged from 30 to 1,140 days (median, 420 days). CONCLUSIONS AND CLINICAL RELEVANCE: The modified proportional margins system resulted in satisfactory local disease control in dogs with MCTs.

Entities:  

Mesh:

Year:  2013        PMID: 24171373     DOI: 10.2460/javma.243.10.1436

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  11 in total

1.  Predictive ability of fine-needle aspirate cytology for incompletely resected mast cell tumor surgical sites.

Authors:  Christopher E Lee; Stephanie S Lindley; Annette N Smith; Philippe Gaillard; Ralph A Henderson; Brad M Matz
Journal:  Can Vet J       Date:  2021-02       Impact factor: 1.008

2.  The effect of prednisone on histologic and gross characteristics in canine mast cell tumors.

Authors:  Ken J Linde; Stephen L Stockdale; Michael B Mison; James A Perry
Journal:  Can Vet J       Date:  2021-01       Impact factor: 1.008

3.  Long-term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs.

Authors:  Teruo Itoh; Atsuko Kojimoto; Kazuyuki Uchida; James Chambers; Hiroki Shii
Journal:  J Vet Med Sci       Date:  2020-12-21       Impact factor: 1.267

4.  Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.

Authors:  Thomas De Ridder; Paul Reddell; Pamela Jones; Graham Brown; Justine Campbell
Journal:  Front Vet Sci       Date:  2021-12-15

Review 5.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

6.  Sentinel Lymph Node Biopsy Is Feasible in Dogs with Scars from Prior Local Excision of Solid Malignancies.

Authors:  Elisa Maria Gariboldi; Damiano Stefanello; Mirja Christine Nolff; Donatella De Zani; Davide Zani; Valeria Grieco; Chiara Giudice; Camilla Recordati; Francesco Ferrari; Roberta Ferrari; Lavinia Elena Chiti
Journal:  Animals (Basel)       Date:  2022-08-26       Impact factor: 3.231

7.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07

8.  A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs.

Authors:  Laura E Selmic; Audrey Ruple
Journal:  BMC Vet Res       Date:  2020-01-06       Impact factor: 2.741

9.  Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.

Authors:  Pamela D Jones; Justine E Campbell; Graham Brown; Chad M Johannes; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-12-22       Impact factor: 3.175

10.  Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46).

Authors:  Thomas R De Ridder; Justine E Campbell; Cheryl Burke-Schwarz; David Clegg; Emily L Elliot; Samuel Geller; Wendy Kozak; Stephen T Pittenger; Jennifer B Pruitt; Jocelyn Riehl; Julie White; Melissa L Wiest; Chad M Johannes; John Morton; Pamela D Jones; Peter F Schmidt; Victoria Gordon; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-06-16       Impact factor: 3.175

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.